EMEA-002255-PIP01-17

Key facts

Active substance
polatuzumab vedotin
Therapeutic area
Oncology
Decision number
P/0117/2018
PIP number
EMEA-002255-PIP01-17
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of mature B-cell neoplasms
Route(s) of administration
Intravenous use
Contact for public enquiries
Roche Registration Limited
Tel. +41 616879411
E-mail: global.paediatrics@roche.com
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating
Average
2 ratings